NcXHF

RESISTANCE TO ANTI-HER2 THERAPIES IN BREAST CANCER
targeted anticancer therapeutics is influenced by the availability of
epidermal growth factor-related peptides. Cancer Res. 2002;62:3151-
3158.
13. Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential
activity against breast cancers driven by HER2 homodimers. Cancer
Res. 2011;71:1871-1882.
14. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology.
2001;61:1-13.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast cancer. N Engl
J Med. 2005;353:1659-1672.
16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy
for operable HER2-positive breast cancer. N Engl J Med.
2005;353:1673-1684.
17. Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-
positive breast cancer: current status and future perspectives. Nat Rev
Clin Oncol. 2012;9:16-32.
18. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the Treatment
of Breast Cancer. Annu Rev Med. 2015;66:111-128.
19. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-
targeted therapies in HER2 gene-amplifıed breast cancer: mechanisms
and clinical implications. Crit Rev Oncog. 2012;17:1-16.
20. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced
attenuation of the growth-inhibitory activity of trastuzumab (Herceptin)
on SKBR3 breast cancer cells. Int J Cancer. 2004;108:334-341.
21. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/
human epidermal growth factor receptor 2 heterodimerization contributes
to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;
65:11118-11128.
22. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player
in oncogenesis and drug resistance. Pharmacol Ther. 2014;142:316-338.
23. Zhang S, Huang WC, Li P, et al. Combating trastuzumab resistance by
targeting SRC, a common node downstream of multiple resistance
pathways. Nat Med. 2011;17:461-469.
24. Chen AC, Migliaccio I, Rimawi M, et al. Upregulation of mucin4 in ERpositive/HER2-overexpressing
breast cancer xenografts with acquired
resistance to endocrine and HER2-targeted therapies. Breast Cancer Res
Treat. 2012;134:583-593.
25. Nahta R, Takahashi T, Ueno NT, et al. P27(kip1) down-regulation is
associated with trastuzumab resistance in breast cancer cells. Cancer
Res. 2004;64:3981-3986.
26. Giuliano M, Wang YC, Gutierrez C, et al. Parallel upregulation of Bcl2
and estrogen receptor (ER) expression in HER2 breast cancer patients
treated with neoadjuvant lapatinib. Cancer Research. 2012;72:24s
(suppl; abstr S5-8).
27. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a
potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent
its onset in breast cancer. Proc Natl Acad SciUSA.2006;103:7795-
7800.
28. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate
in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
29. Beano A, Signorino E, Evangelista A, et al. Correlation between NK
function and response to trastuzumab in metastatic breast cancer patients.
J Transl Med. 2008;6:25.
30. Varchetta S, Gibelli N, Oliviero B, et al. Elements related to heterogeneity
of antibody-dependent cell cytotoxicity in patients under trastuzumab
therapy for primary operable breast cancer overexpressing Her2.
Cancer Res. 2007;67:11991-11999.
31. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C
receptor polymorphisms and clinical effıcacy of trastuzumab-based
therapy in patients with HER-2/neu-positive metastatic breast cancer.
J Clin Oncol. 2008;26:1789-1796.
32. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling
from the structure of the ErbB2-pertuzumab complex. Cancer Cell.
2004;5:317-328.
33. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a
dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2
and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21:6255-
6263.
34. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains
all the mechanisms of action of trastuzumab and effıciently inhibits
growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat.
2011;128:347-356.
35. Brand TM, Iida M, Li C, et al. The nuclear epidermal growth factor receptor
signaling network and its role in cancer. Discovery Medicine.
2011;12:419-432.
36. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal
growth factor receptor 2-overexpressing breast cancer xenografts with
multiagent HER-targeted therapy. J Natl Cancer Inst. 2007;99:694-705.
37. Rimawi MF, Wiechmann LS, Wang YC, et al. Reduced dose and intermittent
treatment with lapatinib and trastuzumab for potent blockade
of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Clin Cancer Res. 2011;17:1351-1361.
38. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase
inhibitor, induces stabilization and accumulation of HER2 and potentiates
trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:
803-814.
39. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel
for HER2-positive metastatic breast cancer (CLEOPATRA
study): overall survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-471.
40. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefıt
with lapatinib in combination with trastuzumab for patients with human
epidermal growth factor receptor 2-positive metastatic breast cancer:
fınal results from the EGF104900 study. J Clin Oncol. 2012;30:2585-
2592.
41. Wang YC, Morrison G, Gillihan R, et al. Different mechanisms for resistance
to trastuzumab versus lapatinib in HER2-positive breast
cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer
Res. 2011;13:R121.
42. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for
HER2-positive early breast cancer (NeoALTTO): a randomised, openlabel,
multicentre, phase 3 trial. Lancet. 2012;379:633-640.
43. Gianni L, Pienkowski T, Im YH, et al. Effıcacy and safety of neoadjuvant
pertuzumab and trastuzumab in women with locally advanced, inflammatory,
or early HER2-positive breast cancer (NeoSphere): a randomised
multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:
25-32.
44. Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component
of neoadjuvant therapy for HER2 operable breast cancer:
NSABP protocol B-41. J Clin Oncol. 2012;30:18s (suppl; abstr LBA506).
45. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in
combination with standard neoadjuvant anthracycline-containing and
anthracycline-free chemotherapy regimens in patients with HER2-
positive early breast cancer: a randomized phase II cardiac safety study
(TRYPHAENA). Ann Oncol. 2013;24:2278-2284.
46. Guarneri V, Frassoldati A, Piacentini F, et al. Preoperative chemotherapy
plus lapatinib or trastuzumab or both in HER2-positive operable
breast cancer (CHERLOB Trial). Clin Breast Cancer. 2008;8:192-194.
47. Carey LA, Barry DA, Ollila D, et al. Clinical and translational results of
CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and
trastuzumab with or without lapatinib for HER2-positive breast cancer.
J Clin Oncol. 2013;31:15s (suppl; abstr 500).
48. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e163